biostudies-literatureUnknown6(9)Vogel B<h4>Importance</h4>Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).<h4>Objective</h4>To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-controlled randomized clinical trial conducted at 187 sites across 11 countries. Study participants included patients who underwent successful PCI with drug-eluting stents, were planned for discharge with ticagrelor plus aspirin, and who had at least 1 clinical and at least 1 angiogrJAMA cardiology1032-1041https://www.ebi.ac.uk/biostudies/studies/S-EPMC8124295biostudies-literatureSex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.PMC8124295Witzenbichler BGil RKunadian VPocock SKaul UFarhan SCollier THuber KGoel RSardella GMehta SRBriguori CGibson CMMehran RDudek DSartori SSharma SKKornowski RMoliterno DOhman EMVogel BEscaned JBaber UAngiolillo DJZhang ZDangas GKrucoff MWHan YLCohen DJfalseSex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.<h4>Importance</h4>Shortened dual antiplatelet therapy followed by potent P2Y12 receptor inhibitor monotherapy reduces bleeding without increasing ischemic events after percutaneous coronary intervention (PCI).<h4>Objective</h4>To explore sex differences and evaluate the association of sex with outcomes among patients treated with ticagrelor monotherapy vs ticagrelor plus aspirin.<h4>Design, setting, and participants</h4>This was a prespecified secondary analysis of TWILIGHT, an investigator-initiated, placebo-controlled randomized clinical trial conducted at 187 sites across 11 countries. Study participants included patients who underwent successful PCI with drug-eluting stents, were planned for discharge with ticagrelor plus aspirin, and who had at least 1 clinical and at least 1 angiogr2021-01-01T00:00:00Z2021 Sep2026-05-09T04:12:06.248Z2024-11-20T17:22:25.783ZS-EPMC81242953399141610.1001/jamacardio.2021.1720